

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)



(10) International Publication Number
WO 2022/208113 A1

(51) International Patent Classification:

A61P 31/14 (2006.01) C07D 405/06 (2006.01)
C07D 209/52 (2006.01) A61K 31/403 (2006.01)
C07D 403/12 (2006.01)

(21) International Application Number:

PCT/GB2022/050836

(22) International Filing Date:

01 April 2022 (01.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2104742.8 01 April 2021 (01.04.2021) GB
2107026.3 17 May 2021 (17.05.2021) GB

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED**
[GB/GB]; Granta Park, Great Abington, Cambridge Cam-
bridgeshire CB21 6DG (GB).

(72) Inventors: **CONGREVE, Miles Stuart**; c/o Heptares
Therapeutics Limited, Granta Park, Great Abington, Cam-
bridge Cambridgeshire CB21 6DG (GB). **CHRISTO-
PHER, John Andrew**; c/o Heptares Therapeutics Limited,
Granta Park, Great Abington, Cambridge Cambridgeshire
CB21 6DG (GB). **PICKWORTH, Mark**; c/o Heptares
Therapeutics Limited, Granta Park, Great Abington, Cam-
bridge Cambridgeshire CB21 6DG (GB). **DE GRAAF,
Chris**; c/o Heptares Therapeutics Limited, Granta Park,
Great Abington, Cambridge Cambridge CB21 6DG (GB).
HIGUERUELO, Alicia Perez; c/o Heptares Therapeutics
Limited, Granta Park, Great Abington, Cambridge Cam-
bridge CB21 6DG (GB). **MASON, Jonathan Stephen**; c/o
Heptares Therapeutics Limited, Granta Park, Great Abing-
ton, Cambridge Cambridge CB21 6DG (GB).

(74) Agent: **GILL JENNINGS & EVERY LLP**; The
Broadgate Tower, 20 Primrose Street, London EC2A 2ES
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SARS-COV-2 MPRO INHIBITOR COMPOUNDS

(57) Abstract: The invention described herein relates to compounds of For-
mula (1b); (1b); or a salt thereof, wherein R¹, R^{1a}, R², R³ and R⁵ are defined
herein, and their use in the treatment of SARS-CoV-2 and related viruses and
disorders associated with SARS-CoV-2.



(1b);

WO 2022/208113 A1